Thesan Pharmaceuticals, a US-based dermatology-focused drugs developer, has received a “golden hello” to the pharma world in the form of $16m series A round co-led by European-based peers Novo Group and Novartis’ corporate venturing units.

The investment will be used by Thesan (whose name is drawn from the eponymous goddess of the dawn and was associated with the generation of life) to get the wheels rolling on its drugs development and underlines an increasing trend in healthcare for more corporate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?